InsiderTrades.com logo
How Low-Cost Stocks Generate Monthly Income
From Darwin   |   Ad
Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!
👉 Yes, I Want the Free Report! 👈
Robert D. Ciappenelli net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Robert Ciappenelli Biography and Net Worth

Insider of Dicerna Pharmaceuticals
Robert D. Ciappenelli serves as Chief Commercial Officer of the Company. Prior to that, Mr. Ciappenelli served as Global Head of Commercial at Momenta Pharmaceuticals (“Momenta”) from January 2016 to October 2018. Prior to Momenta, he held several leadership positions at Shire Pharmaceuticals (now part of Takeda), across commercial operations and business planning. Mr. Ciappenelli’s pharmaceutical commercialization experience also includes various leadership positions at Sunovion Pharmaceuticals, where he served as Vice President of Commercial Operations, Executive Director of Commercial Services and Sales Training and Executive Director of Central Nervous System Marketing. Mr. Ciappenelli earned a Bachelor of Business Administration (B.B.A.) in Finance from the University of Massachusetts at Amherst and a Master of Business Administration (M.B.A.) from the Harvard Graduate School of Business Administration.

What is Robert D. Ciappenelli's net worth?

The estimated net worth of Robert D. Ciappenelli is at least $526,404.06 as of June 14th, 2021. Mr. Ciappenelli owns 13,773 shares of Dicerna Pharmaceuticals stock worth more than $526,404 as of December 23rd. This net worth approximation does not reflect any other investments that Mr. Ciappenelli may own. Learn More about Robert D. Ciappenelli's net worth.

How do I contact Robert D. Ciappenelli?

The corporate mailing address for Mr. Ciappenelli and other Dicerna Pharmaceuticals executives is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. Dicerna Pharmaceuticals can also be reached via phone at (617) 621-8097 and via email at [email protected]. Learn More on Robert D. Ciappenelli's contact information.

Has Robert D. Ciappenelli been buying or selling shares of Dicerna Pharmaceuticals?

Robert D. Ciappenelli has not been actively trading shares of Dicerna Pharmaceuticals during the last quarter. Most recently, Robert D. Ciappenelli sold 20,000 shares of the business's stock in a transaction on Monday, June 14th. The shares were sold at an average price of $38.00, for a transaction totalling $760,000.00. Following the completion of the sale, the insider now directly owns 13,773 shares of the company's stock, valued at $523,374. Learn More on Robert D. Ciappenelli's trading history.

Who are Dicerna Pharmaceuticals' active insiders?

Dicerna Pharmaceuticals' insider roster includes Shreeram Aradhye (EVP), Bob Brown (EVP), Robert Ciappenelli (Insider), Douglas Fambrough (CEO), Marc Kozin (Director), Regina Paglia (Insider), James Weissman (COO), and Ling Zeng (Insider). Learn More on Dicerna Pharmaceuticals' active insiders.

Robert D. Ciappenelli Insider Trading History at Dicerna Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/14/2021Sell20,000$38.00$760,000.0013,773View SEC Filing Icon  
See Full Table

Robert D. Ciappenelli Buying and Selling Activity at Dicerna Pharmaceuticals

This chart shows Robert D Ciappenelli's buying and selling at Dicerna Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dicerna Pharmaceuticals Company Overview

Dicerna Pharmaceuticals logo
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $38.22
Low: $38.22
High: $38.22

50 Day Range

MA: $38.12
Low: $37.81
High: $38.25

2 Week Range

Now: $38.22
Low: $19.06
High: $40.14

Volume

N/A

Average Volume

1,344,033 shs

Market Capitalization

$2.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8
How Low-Cost Stocks Generate Monthly Income
From Darwin   |   Ad
Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!
👉 Yes, I Want the Free Report! 👈